Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade

Immunostimulatory regimens are a game changer in the fight against cancer, but still only a minority of patients achieve clinical benefit. Combination with immunomodulatory drugs and agents converting otherwise non-immunogenic forms of cell death into bona fide “immunogenic cell death” (ICD) could i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kofla, G., Radecke, C., Frentsch, M., Walther, W., Stintzing, S., Riess, H., Bullinger, L., Na, I-K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045824/
https://www.ncbi.nlm.nih.gov/pubmed/35496500
http://dx.doi.org/10.1080/2162402X.2022.2068109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045824/
https://www.ncbi.nlm.nih.gov/pubmed/35496500
http://dx.doi.org/10.1080/2162402X.2022.2068109

Ejemplares similares